Drug Approval | May 12, 2022
OvaCis rapid test to detect ovarian cancer gets CE mark
Revolutionary ovarian cancer rapid test available Q4 2022
Revolutionary ovarian cancer rapid test available Q4 2022
With the commercialization of Qvella technology for Positive Blood Culture (PBC) processing, healthcare facilities can now get results up to 24 hours faster than current methods
Sense anticipates launching Veros Covid-19 in Europe this quarter, initially in Ireland, Benelux and the Nordic regions
The HALO AP platform was developed by Indica Labs to address the specific needs of anatomic pathology labs by supporting a wide range of tissue-based workflows, including primary diagnosis, secondary consults, tumour boards, clinical trials, synoptic reporting, quantitative analytics, and AI
The platform’s technology works as a compression algorithm for molecular testing
The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisions
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
The cloud-based platform enables long-term brain monitoring towards personalized treatment
Three new molecular diagnostic test panels for influenza and other common respiratory illnesses can be run together or alone using one patient sample
Self-collection devices designed for ease of use and safety
Subscribe To Our Newsletter & Stay Updated
